Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of RO5541077 (polatuzumab vedotin) in Japanese Patients with B-cell Non-Hodgkin Lymphoma
jRCT2080222529Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of polatuzumab vedotin in mature B-cell lymphoma, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability of RO5541077 (polatuzumab vedotin). Started Jun 2014; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on jRCT2080222529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222529.